Redefining psychocardiology: Integrating depression management into heart failure care for enhanced long-term recovery and prognosis

Table 1 Representative studies on depression and heart failure: Prevalence, prognosis, and intervention outcomes

Ref.	Design/population	Main focus	Key findings	Main implication
Rutledge et al[1], 2006	Meta-analysis of HF studies	Prevalence and outcomes	Depression is highly prevalent in HF and associated with poorer clinical outcomes	Depression is a highly relevant comorbidity in HF
Jiang et al[15], 2001	Prospective cohort, CHF patients	Mortality and rehospitalization	Depression is associated with increased mortality and rehospitalization risk	Prognostic relevance of depression
Sherwood et al[42], 2007	Prospective cohort, HF patients	Death or hospitalization	Depression predicts death or hospitalization	Depression is a marker of adverse HF prognosis
Sokoreli et al[3], 2016	Systematic review and meta-analysis	Depression/anxiety and mortality	Depression and anxiety predict higher mortality in HF	Supports routine psychosocial risk assessment
Mao et al[19], 2025	Retrospective cohort, HF patients	Ventricular function, adherence, readmission	Greater depression severity is associated with poorer ventricular function, reduced medication adherence, and higher readmission	Supports integration of depression management into HF care
O'Connor et al[30], 2010	Randomized clinical trial	Sertraline in HF with depression	Sertraline does not significantly improve depressive symptoms compared with placebo, and no clear cardiovascular benefit was demonstrated	Antidepressant therapy does not translate into clear HF-specific clinical benefit
Angermann et al[26], 2016	Randomized clinical trial	Escitalopram in HF with depression	No significant reduction in all-cause mortality or hospitalization, and no significant improvement in depressive symptoms	Challenges the assumption that treating depression improves hard HF endpoints
Rollman et al[37], 2021	Randomized clinical trial	Blended collaborative care	Improved mood and mental health-related quality of life, but not rehospitalization or physical function	Collaborative care benefits patient-centered outcomes more than hard endpoints
Freedland et al[28], 2015	Randomized clinical trial	Cognitive behavioral therapy in HF	Benefits for depression and self-care persist at 1 year	Nonpharmacological intervention may improve self-management
Freedland et al[29], 2023	Randomized clinical trial	Depression treatment and self-care	Benefits on depression/self-care persist, but cardiovascular outcome effects remain limited	Supports continued interest in patient-centered outcomes after depression treatment

HF: Heart failure; CHF: Congestive heart failure.

Table 2 Current controversies in psychocardiology for heart failure

Controversy	Supporting rationale	Counterpoint/Limitation	Practical interpretation
Is depression a modifiable causal risk factor or mainly a prognostic marker in HF?	Observational studies consistently show associations with mortality, hospitalization, poor self-care, and reduced quality of life	Randomized trials have not consistently shown reductions in HF hospitalization or mortality after depression treatment	At present, depression in HF may be most appropriately framed as a clinically important prognostic marker and treatment target for symptom burden and self-management
Should routine depression screening be implemented in all HF settings?	Depression is common, under-recognized, and clinically meaningful; tools such as PHQ-2/PHQ-9 are feasible	Screening alone is insufficient if referral pathways, psychiatric support, and follow-up capacity are lacking; moreover, key validation data for common screening strategies were derived mainly from non-HF cardiovascular cohorts	Screening is reasonable only when linked to an actionable care pathway
Do antidepressants improve HF prognosis?	They may be appropriate for selected psychiatric indications, but evidence for HF-specific benefit remains limited	Large trials such as SADHART-CHF and MOOD-HF did not show reduced hard cardiovascular endpoints	Antidepressants should be used cautiously for psychiatric indications, not as established HF outcome-modifying therapy
Can collaborative care improve cardiovascular outcomes?	Collaborative models improve depressive symptoms and mental health-related quality of life	Effects on rehospitalization, physical function, and mortality remain inconsistent	Collaborative care is justified mainly for patient-centered benefits
Can digital health replace face-to-face psychocardiological care?	Telemonitoring, mobile applications, and AI may improve access, monitoring, and longitudinal follow-up	Evidence remains limited, and clinical utility, generalizability, equity, and implementation feasibility are not yet fully established	Digital tools should support, not replace, multidisciplinary human care
Are all HF phenotypes equally affected by depression?	Depression appears relevant across HF populations, including vulnerable and preserved EF groups	Mechanisms and effect sizes may differ by phenotype, socioeconomic context, and comorbidity burden	Precision-oriented psychocardiology is needed

HF: Heart failure; PHQ: Patient Health Questionnaire; AI: Artificial intelligence; CHF: Congestive heart failure.

Table 3 Future research priorities for integrated depression management in heart failure

Priority area	Key research question	Suggested study design	Core outcomes	Why it matters
Integrated stepped-care models	Can embedding depression treatment into optimized HF care reduce recurrent decompensation?	Pragmatic multicenter randomized trial embedded in optimized HF care	Recurrent HF hospitalization or composite HF hospitalization/all-cause death, with depression remission, self-care, and quality of life as key secondary outcomes	Directly tests whether integrated care affects both clinical and patient-centered outcomes
Implementation in real-world settings	How can screening and treatment be integrated into routine HF clinics, including rural and community settings?	Hybrid effectiveness-implementation studies; cluster-randomized trials	Reach, fidelity, feasibility, cost, equity, sustainability, and uptake	Determines whether promising models can be scaled in practice
Precision psychocardiology	Which HF patients are most likely to benefit from targeted depression interventions?	Phenotype-based prospective cohorts and stratified trials	Phenotype stability, symptom trajectories, self-care, functional status, biomarker profiles, and cardiovascular events	Moves the field beyond a one-size-fits-all approach
Digital augmentation of care	Can digital tools improve monitoring, adherence, and early symptom detection when added to standard care?	Randomized pragmatic trials or hybrid effectiveness-implementation studies	Engagement, symptom detection, adherence, self-care, quality of life, readmission	Clarifies the role of digital tools as adjuncts to care
Mechanistic research	Which biological and behavioral pathways most strongly link depression with HF progression?	Translational cohort studies with repeated biomarker and behavioral assessment	Inflammatory markers, autonomic function, sleep disturbance, physical activity, and medication adherence	Helps distinguish causal pathways from epiphenomena
Nonpharmacological intervention strategies	Which psychological or behavioral interventions are most effective in HF?	Comparative effectiveness trials	Depression severity, resilience, exercise tolerance, self-care, quality of life	Helps identify realistic, scalable, and phenotype-sensitive intervention packages

HF: Heart failure.